{"hands_on_practices": [{"introduction": "Effective antimicrobial therapy relies on maintaining drug concentrations at the site of infection that are sufficient to inhibit or kill the pathogen. For a drug like dapsone, which is administered daily over many months, the concept of an average steady-state concentration ($C_{ss}$) becomes critically important. This exercise guides you through a fundamental calculation to determine this average concentration from first principles, connecting the prescribed dose to the resulting drug exposure and its relationship to the Minimum Inhibitory Concentration (MIC) [@problem_id:4978245].", "problem": "A patient with multibacillary leprosy is prescribed oral dapsone once daily. Assume linear pharmacokinetics and a one-compartment model with first-order elimination, and that steady state is achieved under chronic dosing. The oral bioavailability is $F=0.9$, the apparent clearance is $CL=1.5$ $\\mathrm{L/h}$, the dose is $100$ $\\mathrm{mg}$, and the dosing interval is $\\tau=24$ $\\mathrm{h}$. Starting from the definition of clearance as $CL=\\frac{\\text{rate of elimination}}{C}$ and the steady-state mass-balance principle that the average rate of drug input over a dosing interval equals the average rate of drug elimination, derive an expression for the average steady-state plasma concentration $C_{ss}$ for this multiple-dose regimen. Then compute its value for dapsone using the parameters provided. Briefly explain how the computed $C_{ss}$ would compare conceptually to the Minimum Inhibitory Concentration (MIC) for *Mycobacterium leprae* in guiding therapy decisions, without using any additional numerical MIC values. Express your final numerical answer for $C_{ss}$ in $\\mathrm{mg/L}$.", "solution": "The problem statement is evaluated as valid. It is scientifically grounded in fundamental pharmacokinetic principles, self-contained, and well-posed. All necessary parameters are provided, and the objective is clear and formalizable.\n\nThe task is to derive an expression for the average steady-state plasma concentration ($C_{ss}$) and compute its value for a given dapsone regimen. The derivation starts from the steady-state mass-balance principle, which posits that over a single dosing interval, $\\tau$, the average rate of drug input into the systemic circulation is equal to the average rate of drug elimination from the body.\n\nThe average rate of input, $\\text{Rate}_{\\text{in, avg}}$, is determined by the dose ($\\text{Dose}$), the oral bioavailability ($F$), and the dosing interval ($\\tau$). The total amount of drug that enters the systemic circulation per dosing interval is the bioavailable dose, given by the product $F \\times \\text{Dose}$. To find the average rate over the interval, this amount is divided by the duration of the interval, $\\tau$.\n$$\n\\text{Rate}_{\\text{in, avg}} = \\frac{F \\times \\text{Dose}}{\\tau}\n$$\n\nThe average rate of elimination, $\\text{Rate}_{\\text{out, avg}}$, is related to the drug's clearance ($CL$) and its plasma concentration. The problem provides the definition of clearance as the proportionality constant relating the rate of elimination to the plasma concentration, $C(t)$:\n$$\nCL = \\frac{\\text{Rate of elimination}(t)}{C(t)}\n$$\nRearranging this gives the instantaneous rate of elimination:\n$$\n\\text{Rate of elimination}(t) = CL \\times C(t)\n$$\nTo find the average rate of elimination over a dosing interval at steady state, we average this expression over the interval $\\tau$. Assuming linear pharmacokinetics, $CL$ is a constant. The average rate of elimination is therefore the clearance multiplied by the average concentration over the interval. By definition, the average concentration at steady state is $C_{ss}$.\n$$\n\\text{Rate}_{\\text{out, avg}} = CL \\times C_{ss}\n$$\nThis can be shown more formally by integrating the instantaneous rate over the interval:\n$$\n\\text{Rate}_{\\text{out, avg}} = \\frac{1}{\\tau} \\int_{t_{ss}}^{t_{ss}+\\tau} \\text{Rate of elimination}(t) dt = \\frac{1}{\\tau} \\int_{t_{ss}}^{t_{ss}+\\tau} CL \\cdot C(t) dt = CL \\cdot \\left( \\frac{1}{\\tau} \\int_{t_{ss}}^{t_{ss}+\\tau} C(t) dt \\right) = CL \\times C_{ss}\n$$\n\nAccording to the steady-state mass-balance principle, $\\text{Rate}_{\\text{in, avg}} = \\text{Rate}_{\\text{out, avg}}$. Therefore, we can equate the expressions:\n$$\n\\frac{F \\times \\text{Dose}}{\\tau} = CL \\times C_{ss}\n$$\nSolving for $C_{ss}$ yields the desired general expression:\n$$\nC_{ss} = \\frac{F \\times \\text{Dose}}{CL \\times \\tau}\n$$\n\nNext, we compute the numerical value of $C_{ss}$ for dapsone using the given parameters:\n- Dose $= 100$ $\\mathrm{mg}$\n- Bioavailability, $F = 0.9$\n- Clearance, $CL = 1.5$ $\\mathrm{L/h}$\n- Dosing Interval, $\\tau = 24$ $\\mathrm{h}$\n\nSubstituting these values into the derived expression:\n$$\nC_{ss} = \\frac{0.9 \\times 100 \\, \\mathrm{mg}}{1.5 \\, \\mathrm{L/h} \\times 24 \\, \\mathrm{h}}\n$$\nFirst, calculate the product in the numerator and the denominator:\n$$\nC_{ss} = \\frac{90 \\, \\mathrm{mg}}{36 \\, \\mathrm{L}}\n$$\nFinally, perform the division:\n$$\nC_{ss} = 2.5 \\, \\mathrm{mg/L}\n$$\n\nThe average steady-state plasma concentration of dapsone for this patient is $2.5$ $\\mathrm{mg/L}$.\n\nRegarding the conceptual comparison of the computed $C_{ss}$ to the minimum inhibitory concentration ($MIC$): The $MIC$ is the lowest concentration of an antimicrobial agent required to inhibit the visible growth of a microorganism, in this case, *Mycobacterium leprae*. For an antibiotic to be effective, its concentration at the site of infection must be maintained above the $MIC$ for a sufficient period. The average steady-state concentration, $C_{ss}$, is a measure of the overall drug exposure over a dosing interval. In therapeutic drug monitoring, a primary goal is to ensure that drug concentrations, particularly the minimum or trough concentration ($C_{min}$), do not fall below the $MIC$. If the calculated $C_{ss}$ is substantially higher than the known $MIC$ for dapsone against *M. leprae*, it is generally presumed that the concentration will remain above the $MIC$ for most or all of the dosing interval, indicating that the regimen is likely to be therapeutically effective. Conversely, if $C_{ss}$ is found to be close to or below the $MIC$, it raises a significant concern that drug concentrations may fall below the inhibitory level for a substantial portion of the dosing interval, increasing the risk of treatment failure and the selection of drug-resistant bacteria. Thus, the comparison of $C_{ss}$ to $MIC$ is a fundamental pharmacodynamic principle used to guide dosing strategy and predict clinical outcomes.", "answer": "$$\n\\boxed{2.5}\n$$", "id": "4978245"}, {"introduction": "Once therapy is initiated, how do we objectively measure its success? In leprosy, the answer lies in directly observing the drug's effect on the bacteria using two key microscopic measures: the Bacterial Index (BI) and the Morphological Index (MI). This practice challenges you to interpret the distinct trajectories of these indices, reinforcing the crucial difference between killing bacteria and clearing their dead remnants [@problem_id:4978222]. Mastering this concept is essential for accurately tracking a patient's progress and providing confident clinical guidance.", "problem": "A $34$-year-old man with multibacillary leprosy in the borderline lepromatous spectrum begins World Health Organization (WHO) Multi-drug Therapy (MDT) consisting of rifampicin $600$ mg monthly, clofazimine $300$ mg monthly plus $50$ mg daily, and dapsone $100$ mg daily. At baseline, slit-skin smears from $6$ standard sites show a bacterial index (BI) of $4.5$ and a morphological index (MI) of $12\\%$. Smears are repeated at $1$, $6$, and $12$ months.\n\nUsing first principles of bacterial population dynamics under antimicrobial therapy and the standard definitions of smear indices, determine which statements accurately characterize the definitions of BI and MI and predict their trajectories under effective MDT.\n\nA. The bacterial index (BI) is the logarithmic density of acid-fast bacilli (AFB) per oil-immersion field scored $0$–$6$ and averaged across sites; under effective multidrug therapy, BI typically declines slowly, roughly $0.5$–$1.0$ log unit per year because dead bacilli persist in tissues.\n\nB. The morphological index (MI) is the proportion (percentage) of solid-staining, uniformly stained bacilli among at least $200$ counted bacilli; after the first supervised rifampicin dose, MI usually falls rapidly toward $0$ within weeks, reflecting loss of viability.\n\nC. Because rifampicin is rapidly bactericidal, the BI should fall to near $0$ within the first month if therapy is effective.\n\nD. A persistently high BI (for example, $3$–$4$) with an MI of $0$ at $12$ months necessarily indicates treatment failure and ongoing transmission risk.\n\nE. An increase in MI from $2\\%$ to $10\\%$ between months $6$ and $12$ in a previously adherent patient is more consistent with irregular therapy or drug resistance than with an expected pharmacodynamic pattern.", "solution": "The problem statement is a valid clinical scenario in the field of pharmacology and infectious disease, specifically the treatment of leprosy. We first validate the problem statement and then proceed to a detailed analysis of each option.\n\n### Problem Validation\n\n**Step 1: Extract Givens**\n- Patient: A $34$-year-old man.\n- Diagnosis: Multibacillary (MB) leprosy in the borderline lepromatous spectrum.\n- Treatment: World Health Organization (WHO) Multi-drug Therapy (MDT) for MB leprosy.\n- Drug Regimen:\n    - Rifampicin: $600$ mg monthly, supervised.\n    - Clofazimine: $300$ mg monthly, supervised, plus $50$ mg daily.\n    - Dapsone: $100$ mg daily.\n- Baseline Laboratory Data:\n    - Slit-skin smears from $6$ standard sites.\n    - Bacterial Index (BI) = $4.5$.\n    - Morphological Index (MI) = $12\\%$.\n- Follow-up Plan: Smears to be repeated at $1$, $6$, and $12$ months.\n- Question: Evaluate the provided statements regarding the definitions of BI and MI and their expected trajectories under effective MDT, based on first principles of microbiology and pharmacology.\n\n**Step 2: Validate Using Extracted Givens**\n- **Scientifically Grounded**: The problem is based on established clinical practice and scientific principles for the management of leprosy. The diagnosis, WHO-recommended treatment regimen, and monitoring parameters (BI and MI) are standard in leprology. The patient data provided (BI of $4.5$, MI of $12\\%$) are clinically plausible for the diagnosis.\n- **Well-Posed**: The problem is well-posed. It asks for an evaluation of statements against a defined set of principles (bacterial dynamics, definitions of indices). It does not require solving for a single unknown but rather assessing the correctness of qualitative and quantitative claims.\n- **Objective**: The problem is stated in precise, objective, clinical language, free from ambiguity or subjective elements.\n\n**Step 3: Verdict and Action**\n- The problem is scientifically sound, well-posed, and objective. It is **valid**. We may proceed to the solution.\n\n### Derivation from First Principles\n\nLet $N_{total}(t)$ be the total number of *Mycobacterium leprae* bacilli in the host at time $t$. This population can be divided into viable (live) bacilli, $N_{viable}(t)$, and non-viable (dead) bacilli, $N_{dead}(t)$.\n$$N_{total}(t) = N_{viable}(t) + N_{dead}(t)$$\n\nThe two key monitoring parameters, the Bacterial Index (BI) and the Morphological Index (MI), relate to these populations.\n\n1.  **Bacterial Index (BI)**: The BI is a semi-quantitative measure of the total bacterial load, $N_{total}$. It is determined by microscopic examination of slit-skin smears and is reported on Ridley's logarithmic scale, which ranges from $0$ to $6+$. A higher BI corresponds to a higher density of acid-fast bacilli (AFB), counting both live and dead organisms. The dynamics of BI are governed by the change in the total population:\n    $$\\frac{d(\\text{BI})}{dt} \\propto \\frac{d(\\log N_{total})}{dt} = \\frac{1}{N_{total}} \\frac{dN_{total}}{dt}$$\n    Effective therapy rapidly kills bacteria, converting $N_{viable}$ to $N_{dead}$. However, the clearance of dead bacilli and their antigenic debris by the host's macrophages is an extremely slow process for *M. leprae*. Therefore, while $N_{viable}$ drops quickly, $N_{dead}$ initially increases and then decreases very slowly. As a result, $N_{total}$ declines at a slow rate, determined primarily by the host's clearance capacity.\n\n2.  **Morphological Index (MI)**: The MI is the proportion of viable bacilli within the total population. Microscopically, viable bacilli are identified as solid-staining and uniformly shaped, while non-viable bacilli appear fragmented or granular. The MI is defined as:\n    $$MI(t) = \\frac{N_{viable}(t)}{N_{total}(t)} \\times 100\\%$$\n    The WHO-MDT regimen includes rifampicin, a potent and rapidly bactericidal drug. The first monthly supervised dose of rifampicin kills a very large fraction of the viable bacilli population. Therefore, $N_{viable}(t)$ is expected to decrease sharply and rapidly upon initiation of effective therapy. This leads to a correspondingly rapid fall in the MI.\n\n### Option-by-Option Analysis\n\n**A. The bacterial index (BI) is the logarithmic density of acid-fast bacilli (AFB) per oil-immersion field scored $0$–$6$ and averaged across sites; under effective multidrug therapy, BI typically declines slowly, roughly $0.5$–$1.0$ log unit per year because dead bacilli persist in tissues.**\n- **Analysis**: This statement correctly defines the BI as a logarithmic score ($0$–$6$) representing the density of total AFB. It also correctly predicts its trajectory. As derived from first principles, the BI reflects $N_{total}$. Since the clearance of dead *M. leprae* is very slow, $N_{total}$ decreases slowly even when all viable bacteria have been killed. The clinically observed rate of decline of approximately $0.5$ to $1.0$ log unit per year is a direct consequence of this slow clearance. The initial BI is $4.5$; after one year, a BI in the range of $3.5$ to $4.0$ would be expected. The statement is entirely consistent with established principles and clinical observations.\n- **Verdict**: **Correct**.\n\n**B. The morphological index (MI) is the proportion (percentage) of solid-staining, uniformly stained bacilli among at least $200$ counted bacilli; after the first supervised rifampicin dose, MI usually falls rapidly toward $0$ within weeks, reflecting loss of viability.**\n- **Analysis**: This statement correctly defines the MI as the percentage of morphologically intact (solid-staining) bacilli, which are surrogates for viability. The prediction of its trajectory is also accurate. Rifampicin exerts a powerful and rapid bactericidal effect on *M. leprae*. This causes $N_{viable}$ to plummet. Consequently, the MI, which is the ratio of $N_{viable}$ to $N_{total}$, should fall dramatically towards $0$ shortly after treatment begins. A fall from the initial $12\\%$ to near $0$ within a few weeks to a couple of months is the expected and desired therapeutic response.\n- **Verdict**: **Correct**.\n\n**C. Because rifampicin is rapidly bactericidal, the BI should fall to near $0$ within the first month if therapy is effective.**\n- **Analysis**: This statement incorrectly conflates bactericidal activity with bacterial clearance. While rifampicin is indeed rapidly bactericidal, this affects the MI, not the BI. The BI measures the total bacterial mass (live + dead). The dead bacilli killed by rifampicin remain in the tissues and continue to be stained by the Ziehl-Neelsen method, thus contributing to the BI count. As clearance is very slow, the BI will remain high for months to years. A fall of the BI to near $0$ in one month is biologically impossible and contradicts established knowledge.\n- **Verdict**: **Incorrect**.\n\n**D. A persistently high BI (for example, $3$–$4$) with an MI of $0$ at $12$ months necessarily indicates treatment failure and ongoing transmission risk.**\n- **Analysis**: This statement is a complete misinterpretation of the clinical data. A BI of $3$–$4$ at $12$ months, starting from a baseline of $4.5$, is an expected finding, reflecting the slow clearance of dead bacilli (as per option A). An MI of $0$ indicates that no viable bacilli were detected, which is the primary goal of therapy and the hallmark of a successful bacteriological response. A patient with an MI of $0$ is considered non-infectious, so there is no ongoing transmission risk. The combination of a high but falling BI and an MI of $0$ represents treatment success, not failure.\n- **Verdict**: **Incorrect**.\n\n**E. An increase in MI from $2\\%$ to $10\\%$ between months $6$ and $12$ in a previously adherent patient is more consistent with irregular therapy or drug resistance than with an expected pharmacodynamic pattern.**\n- **Analysis**: The expected pharmacodynamic pattern is a rapid fall and subsequent suppression of the MI at or near $0\\%$. An MI of $2\\%$ at $6$ months is already a cause for some concern, but an *increase* to $10\\%$ by $12$ months is a definitive sign of treatment failure. It means that the population of viable bacteria, $N_{viable}$, is growing again. This rebound is fundamentally inconsistent with the effects of an effective drug regimen. The most common causes for such a rebound are: 1) non-adherence to therapy (irregular therapy), allowing surviving bacteria to regrow, or 2) the emergence of a bacterial population resistant to the drugs, rendering the therapy ineffective. The statement correctly identifies these possibilities and contrasts them with the expected pattern.\n- **Verdict**: **Correct**.", "answer": "$$\\boxed{ABE}$$", "id": "4978222"}, {"introduction": "The global strategy for leprosy control is built on the foundation of Multi-Drug Therapy (MDT). But why is combination therapy so vastly superior to using a single drug? The answer lies in the evolutionary dynamics of drug resistance. This advanced exercise invites you to explore this question quantitatively using the principle of mutation-selection balance. You will calculate how MDT fundamentally alters the selective pressures on the bacterial population, making the emergence of resistant strains a far rarer event than under monotherapy [@problem_id:4978208].", "problem": "A public health program for Hansen’s disease (leprosy) transitions from historical dapsone monotherapy to modern Multi-Drug Therapy (MDT). You are asked to estimate the expected equilibrium prevalence of dapsone-resistant alleles in the bacterial population of Mycobacterium leprae using mutation–selection balance under two environmental classes: inappropriate monotherapy and correct MDT.\n\nAssume the following scientifically standard bases:\n- In a large, haploid, clonally reproducing population with forward mutation rate $\\,\\mu\\,$ per genome per generation to a resistant allele, and a constant selection coefficient $\\,s\\,$ against that resistant allele in a given environment (so the resistant genotype has relative fitness $\\,1 - s\\,$ and the wild type has relative fitness $\\,1\\,$), a mutation–selection equilibrium can arise when $\\,\\mu \\ll 1\\,$ and $\\,s > 0\\,$.\n- Let the fraction of bacterial generations occurring under inappropriate monotherapy be $\\,p\\,$ and under MDT be $\\,1-p\\,$. Assume rapid mixing across hosts so that the overall expected prevalence of resistance is the weighted average across these two environmental classes at their respective equilibria.\n\nIn this setting, due to adherence gaps and the intrinsic fitness cost of resistance, the net selection coefficient against resistance during inappropriate monotherapy is empirically small but positive, $\\,s_{\\mathrm{mono}} = 5 \\times 10^{-6}\\,$. Under MDT, the combined regimen eliminates any advantage of resistance to dapsone and amplifies fitness costs, yielding $\\,s_{\\mathrm{MDT}} = 2 \\times 10^{-3}\\,$. The forward mutation rate to resistance is $\\,\\mu = 2 \\times 10^{-8}\\,$, and the fraction of bacterial generations under inappropriate monotherapy is $\\,p = 1 \\times 10^{-1}\\,$.\n\nUsing only the above fundamental framework, derive from first principles the expected overall equilibrium prevalence of dapsone-resistant alleles across the entire bacterial population as a decimal fraction. Round your final answer to three significant figures. Express the final result with no units.", "solution": "The problem asks for the expected overall equilibrium prevalence of dapsone-resistant alleles in a *Mycobacterium leprae* population under a mixed environment of inappropriate monotherapy and correct Multi-Drug Therapy (MDT). The solution will be derived from the first principles of mutation-selection balance.\n\nFirst, let us establish the fundamental model for mutation-selection balance in a large, haploid, clonally reproducing population. Let $q$ be the frequency of a mutant allele (in this case, the dapsone-resistant allele) and $1-q$ be the frequency of the wild-type allele. The forward mutation rate from wild-type to the mutant allele is given as $\\mu$ per generation. The selection coefficient against the mutant allele is $s$, so its relative fitness is $1-s$ compared to the wild-type fitness of $1$.\n\nThe change in the frequency of the resistant allele, $\\Delta q$, in one generation is the sum of the increase due to mutation and the decrease due to selection.\n\nThe increase due to mutation, $\\Delta q_{\\text{mut}}$, arises from wild-type bacteria mutating into resistant ones. This is given by the mutation rate multiplied by the frequency of the wild-type population:\n$$\n\\Delta q_{\\text{mut}} = \\mu (1-q)\n$$\n\nThe change due to selection, $\\Delta q_{\\text{sel}}$, is determined by the differential survival of the resistant and wild-type alleles. After one generation of selection, the frequency of the resistant allele, $q'$, is its initial frequency $q$ times its relative fitness $1-s$, divided by the mean fitness of the population, $\\bar{w}$.\n$$\n\\bar{w} = q(1-s) + (1-q)(1) = 1 - sq\n$$\nThus, the frequency after selection is:\n$$\nq' = \\frac{q(1-s)}{\\bar{w}} = \\frac{q(1-s)}{1 - sq}\n$$\nThe change in frequency due to selection is:\n$$\n\\Delta q_{\\text{sel}} = q' - q = \\frac{q(1-s)}{1 - sq} - q = \\frac{q(1-s) - q(1 - sq)}{1 - sq} = \\frac{q - qs - q + sq^2}{1 - sq} = \\frac{-qs + sq^2}{1 - sq} = \\frac{-sq(1-q)}{1 - sq}\n$$\n\nAt equilibrium, the total change in allele frequency per generation is zero, i.e., $\\Delta q = \\Delta q_{\\text{mut}} + \\Delta q_{\\text{sel}} = 0$.\n$$\n\\mu(1-q) + \\frac{-sq(1-q)}{1 - sq} = 0\n$$\nSince the equilibrium frequency $q_{\\text{eq}}$ is expected to be small and not equal to $1$, we can divide by the term $(1-q)$:\n$$\n\\mu = \\frac{sq}{1 - sq}\n$$\nSolving for $q$, we get:\n$$\n\\mu(1-sq) = sq \\implies \\mu - \\mu sq = sq \\implies \\mu = sq + \\mu sq = q(s + \\mu s)\n$$\nThe exact equilibrium frequency, $q_{\\text{eq}}$, is:\n$$\nq_{\\text{eq}} = \\frac{\\mu}{s(1+\\mu)}\n$$\nThe problem states that we are in a regime where $\\mu \\ll 1$. In this case, the term $(1+\\mu) \\approx 1$, and the expression for the equilibrium frequency simplifies to the standard approximation:\n$$\nq_{\\text{eq}} \\approx \\frac{\\mu}{s}\n$$\nThis formula provides the equilibrium prevalence of the resistant allele in a single, constant environment.\n\nThe problem describes two distinct environmental classes: inappropriate monotherapy and correct MDT, each with its own selection coefficient. Let $q_{\\text{mono}}$ and $q_{\\text{MDT}}$ be the equilibrium allele prevalences in these respective environments.\n\nFor the monotherapy environment, the selection coefficient is $s_{\\text{mono}} = 5 \\times 10^{-6}$. The equilibrium prevalence is:\n$$\nq_{\\text{mono}} \\approx \\frac{\\mu}{s_{\\text{mono}}}\n$$\n\nFor the MDT environment, the selection coefficient is $s_{\\text{MDT}} = 2 \\times 10^{-3}$. The equilibrium prevalence is:\n$$\nq_{\\text{MDT}} \\approx \\frac{\\mu}{s_{\\text{MDT}}}\n$$\n\nThe problem states that the overall expected equilibrium prevalence, $q_{\\text{overall}}$, is the weighted average of the prevalences in these two environments. The weights are the fraction of bacterial generations occurring under each condition, given as $p$ for monotherapy and $1-p$ for MDT.\n$$\nq_{\\text{overall}} = p \\cdot q_{\\text{mono}} + (1-p) \\cdot q_{\\text{MDT}}\n$$\nSubstituting the expressions for $q_{\\text{mono}}$ and $q_{\\text{MDT}}$:\n$$\nq_{\\text{overall}} \\approx p \\left(\\frac{\\mu}{s_{\\text{mono}}}\\right) + (1-p) \\left(\\frac{\\mu}{s_{\\text{MDT}}}\\right)\n$$\nWe can factor out the mutation rate $\\mu$:\n$$\nq_{\\text{overall}} \\approx \\mu \\left(\\frac{p}{s_{\\text{mono}}} + \\frac{1-p}{s_{\\text{MDT}}}\\right)\n$$\n\nNow, we substitute the given numerical values into this expression:\n$\\mu = 2 \\times 10^{-8}$\n$p = 1 \\times 10^{-1} = 0.1$\n$1-p = 1 - 0.1 = 0.9$\n$s_{\\text{mono}} = 5 \\times 10^{-6}$\n$s_{\\text{MDT}} = 2 \\times 10^{-3}$\n\n$$\nq_{\\text{overall}} \\approx (2 \\times 10^{-8}) \\left(\\frac{0.1}{5 \\times 10^{-6}} + \\frac{0.9}{2 \\times 10^{-3}}\\right)\n$$\nFirst, we evaluate the terms inside the parentheses:\n$$\n\\frac{0.1}{5 \\times 10^{-6}} = \\frac{1 \\times 10^{-1}}{5 \\times 10^{-6}} = \\frac{1}{5} \\times 10^{5} = 0.2 \\times 10^{5} = 2 \\times 10^{4}\n$$\n$$\n\\frac{0.9}{2 \\times 10^{-3}} = 0.45 \\times 10^{3} = 450\n$$\nNow, substitute these back into the expression for $q_{\\text{overall}}$:\n$$\nq_{\\text{overall}} \\approx (2 \\times 10^{-8}) \\left(2 \\times 10^{4} + 450\\right)\n$$\n$$\nq_{\\text{overall}} \\approx (2 \\times 10^{-8}) (20000 + 450) = (2 \\times 10^{-8}) (20450)\n$$\n$$\nq_{\\text{overall}} \\approx (2 \\times 10^{-8}) (2.045 \\times 10^{4})\n$$\n$$\nq_{\\text{overall}} \\approx (2 \\times 2.045) \\times 10^{-8+4} = 4.09 \\times 10^{-4}\n$$\n\nThe expected overall equilibrium prevalence of dapsone-resistant alleles across the entire bacterial population is $4.09 \\times 10^{-4}$. The problem asks for this as a decimal fraction rounded to three significant figures. The calculated value $4.09 \\times 10^{-4}$ is already in scientific notation with three significant figures. As a decimal, this is $0.000409$.", "answer": "$$\\boxed{4.09 \\times 10^{-4}}$$", "id": "4978208"}]}